Pharmacia R&D Head Ando Leaves For Celltech; Will Still Work With Pfizer
Executive Summary
Pharmacia R&D President Goran Ando, MD, will move to the other side of a partnership between Pharmacia and Celltech for the Phase III rheumatoid arthritis agent CDP-870 as Celltech CEO
You may also be interested in...
UCB Acquiring Celltech; Phase III TNF Inhibitor At Center Of $2.7 Bil. Deal
UCB is paying $2.7 bil. to lock up rights to Celltech's TNF inhibitor CDP-870
UCB Acquiring Celltech; Phase III TNF Inhibitor At Center Of $2.7 Bil. Deal
UCB is paying $2.7 bil. to lock up rights to Celltech's TNF inhibitor CDP-870
Pharmacia Farms Out CEOs: Rothwell To Head Sanofi North America
Sanofi-Synthelabo North America CEO-designate Tim Rothwell will bring extensive experience in the low-molecular weight heparin category to help re-energize the launch of Arixtra